Five years ago, immunotherapy was a footnote in mesothelioma treatment. Today it is one of the most important advances in the disease’s history. The drugs nivolumab and ipilimumab, sold as Opdivo and Yervoy, are now first-line treatment for many patients with pleural mesothelioma that cannot be removed by surgery. Newer immunotherapies are emerging every year.
This guide explains mesothelioma immunotherapy in plain language. You will learn how immunotherapy differs from chemotherapy, which drugs are approved for mesothelioma, who is a candidate, what side effects to expect, what response and survival data look like, and what new immunotherapy approaches are coming through clinical trials.
How Immunotherapy Differs From Chemotherapy
Chemotherapy attacks cancer cells directly with drugs that damage DNA or block cell division. Immunotherapy works through a different mechanism. It helps your own immune system recognise cancer cells as threats and destroy them. The cancer-killing is done by your T cells, the soldiers of your immune system, which have been activated by the immunotherapy drug.
The reason immunotherapy is needed is that cancer cells often hide from the immune system using molecular tricks. They display proteins on their surface that essentially tell T cells “do not attack me.” Immunotherapy drugs called checkpoint inhibitors block these proteins, removing the cancer’s invisibility cloak. Once the T cells can see the cancer, they engage and attack.
The Approved Combination: Opdivo Plus Yervoy
For unresectable pleural mesothelioma, the FDA-approved first-line combination is nivolumab plus ipilimumab. Nivolumab is a PD-1 checkpoint inhibitor. It blocks the PD-1 protein on T cells from interacting with the PD-L1 protein on cancer cells, restoring the T cells’ ability to attack. Ipilimumab is a CTLA-4 checkpoint inhibitor. It works at an earlier step of immune activation, helping T cells get primed to attack in the first place.
The two drugs target different brakes on the immune system. Removing both brakes simultaneously produces stronger anti-cancer activity than either drug alone. The combination was approved based on the CheckMate 743 trial, which showed a meaningful survival improvement over standard chemotherapy in patients with unresectable mesothelioma. The benefit was particularly strong in patients with sarcomatoid or biphasic cell types, which historically respond poorly to chemotherapy.
The Treatment Schedule
The Opdivo-Yervoy combination is given by IV infusion. Nivolumab is administered every two weeks or every four weeks depending on the protocol. Ipilimumab is given every six weeks. Treatment continues for up to two years, or until disease progression or unacceptable side effects, whichever comes first.
Each infusion takes thirty to ninety minutes. Side effects can occur during the infusion or in the days and weeks afterward. Many patients tolerate the infusions themselves easily. The challenges, when they arise, come from the immune-related adverse events that can develop over time.
Side Effects: A Different Pattern Than Chemotherapy
Immunotherapy side effects are different from chemotherapy side effects. Because the drug is activating the immune system rather than killing cells directly, the side effects are often immune-related rather than cytotoxic. The activated immune system can attack healthy tissue along with cancer tissue. The most common immune-related adverse events include skin rashes, colitis with diarrhoea, hepatitis affecting liver function, hypothyroidism, hypophysitis affecting pituitary function, and pneumonitis affecting the lungs.
Most of these are manageable when caught early. Many resolve with corticosteroid treatment that calms the over-activated immune response. The key is recognising symptoms early and reporting them. Diarrhoea that lasts more than a day, a new rash, unexplained fatigue, shortness of breath, or any new symptom during immunotherapy deserves a phone call to the oncology team. The earlier the response, the better the outcome.
Some immune-related adverse events are permanent. Thyroid damage often requires lifelong thyroid hormone replacement. Pituitary damage can require lifelong cortisol replacement. The trade-off is generally accepted because these are manageable with daily medications, while the alternative is uncontrolled mesothelioma.
Who Is a Candidate
The first-line use of Opdivo plus Yervoy is approved for adults with unresectable pleural mesothelioma. Resectable patients are typically directed to surgery first. Patients with peritoneal mesothelioma can be considered for immunotherapy in some cases, particularly when surgery is not an option, though the formal approval was for pleural disease. Off-label use for peritoneal mesothelioma is increasingly common at major centres.
Performance status matters. Patients who are too sick to tolerate the immune side effects, who have active autoimmune diseases, or who have organ transplants on immunosuppression are generally not candidates. The decision is individualised.
Response and Survival Data
In the CheckMate 743 trial, median survival with Opdivo-Yervoy was approximately eighteen months for patients with unresectable pleural mesothelioma, compared to approximately fourteen months with standard chemotherapy. The improvement was particularly pronounced for sarcomatoid and biphasic cell types, where median survival nearly doubled. For epithelioid mesothelioma, the difference was more modest, with chemotherapy-immunotherapy combinations now being investigated to improve outcomes further.
Long-term survival data continues to mature. Some patients on immunotherapy show durable responses lasting years, sometimes appearing as if the disease has stopped progressing entirely. These long-term responders are a notable feature of immunotherapy that was not seen with chemotherapy alone. Predicting which patients will be long-term responders is an active area of research.
Newer Immunotherapy Approvals
The field is moving quickly. Several other checkpoint inhibitors are approved or in late-stage trials for mesothelioma. Pembrolizumab (Keytruda) is sometimes used in second-line settings. Tremelimumab combined with durvalumab is approved for some indications. Tumour-infiltrating lymphocyte therapy and CAR-T approaches specific to mesothelioma are in clinical trials.
The combination of chemotherapy plus immunotherapy is being tested in major trials. Early data suggests the triple combination of pemetrexed, cisplatin or carboplatin, and an immunotherapy agent may produce better outcomes than chemotherapy alone or immunotherapy alone for some patients. Approval decisions for these combinations are expected over the next few years.
Clinical Trial Considerations
Clinical trials are an important pathway to access newer immunotherapies before they receive FDA approval. Major mesothelioma treatment centers maintain active trial portfolios. Patients diagnosed with mesothelioma should ask their oncologist explicitly whether trial enrolment is appropriate at the current treatment phase.
Trials are competitive. Eligibility criteria are specific. Some trials require enrolment before starting any first-line therapy. Others enrol patients after disease progression on standard treatment. Knowing which trials are open at which centres, and timing enrolment correctly, can be the difference between accessing a breakthrough therapy and missing the window.
A Realistic Closing Note
Immunotherapy has changed the landscape of mesothelioma treatment. It is not a cure. It does not work for every patient. The side effects, when they occur, can be serious. But for many patients, particularly those with sarcomatoid or biphasic cell types who historically had few options, immunotherapy has produced meaningful and sometimes durable responses that were not available a decade ago.
If you are considering immunotherapy, ask your oncology team about the specific protocol they recommend, the expected response based on your tumour cell type and biomarkers, the side effects you should watch for, and the trial options that may be appropriate. The conversation is worth having early, while you have time to weigh choices.
This article is for educational purposes and does not replace personalised guidance from a medical oncologist. Discuss treatment options with your treating team.